Interferon regulatory factor (IRF) 3 is critical for the development of experimental autoimmune encephalomyelitis

Background Experimental autoimmune encephalomyelitis (EAE) is an animal model of autoimmune inflammatory demyelination that is mediated by Th1 and Th17 cells. The transcription factor interferon regulatory factor 3 (IRF3) is activated by pathogen recognition receptors and induces interferon-β production. Methods To determine the role of IRF3 in autoimmune inflammation, we immunised wild-type (WT) and irf3−/− mice to induce EAE. Splenocytes from WT and irf3−/− mice were also activated in vitro in Th17-polarising conditions. Results Clinical signs of disease were significantly lower in mice lacking IRF3, with reduced Th1 and Th17 cells in the central nervous system. Peripheral T-cell responses were also diminished, including impaired proliferation and Th17 development in irf3−/− mice. Myelin-reactive CD4+ cells lacking IRF3 completely failed to transfer EAE in Th17-polarised models as did WT cells transferred into irf3−/− recipients. Furthermore, IRF3 deficiency in non-CD4+ cells conferred impairment of Th17 development in antigen-activated cultures. Conclusion These data show that IRF3 plays a crucial role in development of Th17 responses and EAE and warrants investigation in human multiple sclerosis.

Interferon regulatory factor 3 (IRF3) is a transcription factor that, together with IRF7 and nuclear factor-κB (NF-κB), is activated by antiviral pattern recognition receptors. IRF3 activation is part of the first line of defence against invading viruses, and its activation results in the production of IFN-β. This in turn, induces an amplification loop of type I IFN, which leads to the development of an antiviral state [5][6][7]. The importance of IRF3 in the development of antiviral immunity has been shown by using IRF3-deficient animals, which are more susceptible to viral infection. In addition, IRF3/IRF7 double-knockouts do not produce IFN-γ in response to viruses and are severely impaired in their antiviral responses [8].
The role of IRFs in EAE and MS has received limited attention. Tada and colleagues showed that IRF1 plays a proinflammatory role in EAE [11], and, recently, Huber et al. showed that IRF4 promotes CD8 + T-cell-mediated EAE [12]. Tzima et al. found that mice with heme oxygenase 1 deficiency in myeloid cells exhibited enhanced EAE severity which was associated with a lack of IRF3 activation [13]. To our knowledge, our present study is the first in which the impact of IRF3 deficiency in EAE has been investigated.
On the basis of previous studies showing the protective effect of type I IFN signalling in EAE [14][15][16][17], we expected irf3 −/− mice to develop more severe EAE. Compellingly, irf3 −/− mice in fact developed significantly less severe EAE with less CNS infiltration and diminished T-cell responses, including proliferation and Th17 development. Furthermore, myelin-reactive CD4 + T cells lacking IRF3 completely failed to transfer EAE in an IL-23-driven, Th17-biased model, as did WT cells transferred into irf3 −/− recipients. IRF3 deficiency in non-CD4 + cells, but not in CD4 + cells, conferred impairment of Th17 development in antigen-activated cultures. These data implicate IRF3 in the pathogenesis of autoimmune inflammation and Th17 responses.

Experimental autoimmune encephalomyelitis induction
EAE was actively induced in 8-to 12-week-old female C57BL/6 mice (The Jackson Laboratory, Bar Harbor, ME, USA) and irf3 −/− mice by subcutaneous injection of 150 μg of myelin oligodendrocyte glycoprotein (MOG 35-55 ) in complete Freund's adjuvant (CFA) medium containing 5 mg/ml Mycobacterium tuberculosis. Bordetella pertussis toxin (PT) was administered intraperitoneally (200 ng/ mouse) on day 0 and day 2. To adoptively transfer EAE, C57BL/6 or irf3 −/− mice were immunised subcutaneously with 200 μg of MOG  in CFA medium at four sites on the back. Mice were sacrificed after 9 to 12 days, and their lymph nodes and spleens were retrieved. Cells were cultured (spleens and lymph nodes combined) at a density of 8 × 10 6 cells/ml in RPMI 1640 medium with 10% foetal calf serum (FCS) and penicillin-streptomycin, L-glutamine, 2-mercaptoethanol, 2-[4-(2-hydroxyethyl)piperazin-1yl]ethanesulfonic acid and sodium pyruvate in 150 × 25-mm Petri dishes. Cells were cultured for 3 days with IL-23 (20 ng/ml) at 37°C recovered, and CD4 + cells were purified with anti-CD4-conjugated magnetic beads (Miltenyi Biotec, Surrey, UK). Cells were resuspended in phosphate-buffered saline (PBS), and 5 × 10 6 cells were injected via the tail vein into recipient mice. PT was injected intraperitoneally (200 ng/injection) on day 0 and day 2. Mice were scored daily for clinical signs of disease according to the following scale: partial limp tail, 0.5; full limp tail, 1; limp tail and waddling gait, 1.5; paralysis of one hindlimb, 2; paralysis of one hindlimb and partial paralysis of other hindlimb, 2.5; paralysis of both hindlimbs, 3; ascending paralysis, 3.5; paralysis of trunk, 4; moribund, 4.5; death, 5. Cumulative scores were calculated by adding together all daily scores for an individual mouse to yield a single cumulative score value for each mouse. All studies were performed with the approval of the institutional animal care and use committee of Thomas Jefferson University (Philadelphia, PA, USA) or in compliance with the UK Home Office and approved by the Queen's University Ethical Review Committee.

Isolation of central nervous system cells
Spinal cords were removed from the mice after transcardial perfusion with PBS. Mononuclear cells were isolated by Percoll gradient centrifugation. Pooled cells were cultured for 4 hours in RPMI 1640 medium containing 10% FCS and stimulated with phorbol 12-myristate 13-acetate (50 ng/ml), ionomycin (500 ng/ml) and GolgiPlug protein transport inhibitor (1 μg/10 6 cells; BD Biosciences, San Jose, CA, USA).

Flow cytometry
Flow cytometric analysis of splenocytes and mononuclear cells from the CNS was performed as previously described [18]. Briefly, cells were washed and blocked with anti-CD16/anti-CD32 antibodies. Blocked cells were stained for 20 minutes in the dark with fluorescencelabelled antibodies to a range of cell surface markers (BD Pharmingen, San Diego, CA, USA). For intracellular staining, cells were washed, fixed and permeabilised using FIX & PERM cell permeabilisation reagents (Caltag Laboratories, Burlingame, CA, USA). Cells were intracellularly stained for IL-17 and IFN-γ. Data were acquired on a FACSAria or FACSCanto system (BD Biosciences) and analysed using FlowJo software (TreeStar, Ashland, OR, USA).

Statistical analysis
Clinical scores were tested for statistical significance by comparing areas under the curve for each animal and comparing groups with a nonparametric Mann-Whitney U test. Cytokine production and proliferative responses of WT and irf3 −/− mice were compared using an unpaired two-tailed Student's t test.

Deficiency of interferon regulatory factor 3 inhibits experimental autoimmune encephalomyelitis
To investigate the role of IRF3 in CNS autoimmune inflammation, we induced EAE in WT and irf3 −/− mice with MOG 35-55 in CFA medium. Surprisingly, we consistently observed significantly less severe disease in irf3 −/− mice ( Figure 1A). Disease incidence was also significantly lower in irf3 −/− groups (Table 1), as were maximal and cumulative clinical scores in five independent experiments ( Figures 1B and 1C). These data indicate that IRF3 contributes to the pathogenesis of EAE.
To investigate potential roles of IRF3 in EAE pathogenesis, we examined CNS inflammatory infiltrates. We observed fewer total cells in pooled spinal cords of irf3 −/− mice with EAE than in their WT counterparts (Figure 2A). We analysed infiltrates by flow cytometry and observed slightly lower proportions of both CD4 + and CD8 + cells in the CNS of irf3 −/− mice ( Figure 2B). Given the central role for CD4 + T cells in EAE pathogenesis, we examined the helper T cell subsets in the CNS infiltrate. We observed a lower proportion of both Th1 (CD4 + IFN-γ + ) and Th17 (CD4 + IL-17 + ) cells, as well as CD4 + cells, producing both IFN-γ and IL-17 in irf3 −/− mice ( Figure 2C).
We next examined the peripheral immune response in spleens of immunised WT and irf3 −/− mice. We observed significantly lower proliferative responses to polyclonal stimulation in splenocytes of irf3 −/− mice ( Figure 3A). There was also a trend towards reduced antigen-specific proliferation to MOG 35-55 ( Figure 3A). We next examined  Table 1). Mean maximal (B) and cumulative (C) clinical scores reached in irf3 −/− and WT mice in five independent experiments over the full duration of disease are shown. cytokine production in splenocytes activated with anti-CD3/anti-CD28 or with MOG 35-55 . Expression of IL-17 was significantly lower in splenocytes from irf3 −/− mice that were polyclonally activated or activated with MOG 35-55 ( Figure 3B), suggesting that IRF3 may play a role in IL-17 production by T cells.

IRF3 deficiency impairs Th17 differentiation
As both Th1 and Th17 cells were found at lower frequencies in the CNS of irf3 −/− mice with EAE than in the WT mice ( Figure 2C), we investigated the impact of IRF3 deficiency on Th1 and Th17 differentiation in vitro. Consistently, IRF3 deficiency resulted in increased proportions of Th1 cells (CD4 + IFN-γ + ) in all conditions tested ( Figure 4A). Conversely, proportions of Th17 cells (CD4 + IL-17 + ) were lower in irf3 −/− cultures than in WT cultures in Th17polarised cultures ( Figure 4A), the only condition in which robust IL-17 expression was observed (TGF β + IL-6 + IL-1β + anti-IFN-γ). These findings demonstrate that IRF3 mediates helper T cell polarisation with opposing supportive and inhibitory effects on Th17 and Th1 differentiation, respectively. Thus, although proportions of both Th1 and Th17 subsets were reduced in the CNS of mice with EAE ( Figure 2C), it is likely that reduced Th17 development was a limiting factor in the development of EAE in irf3 −/− mice. Of note, certain Th17 polarisation experiments included neutralising anti-IFN-γ antibody to ensure that differences were not due to the observed increase in IFN-γ production in the absence of IRF3 ( Figure 4A). We also examined additional Th17-polarising cytokine cocktails that support de novo differentiating (TGF-β + IL-6 + IL-1β + TNF-α) and differentiated (IL-23) Th17 cells, and we consistently observed less IL-17 production in IRF3-deficient cultures ( Figure 4B). These data provide strong evidence that IRF3 is involved in Th17 cell development and function.

IRF3-deficient T cells fail to transfer experimental autoimmune encephalomyelitis
To investigate the role of IRF3 specifically in Th17cell pathogenicity, we used a Th17-biased model of adoptively transferred EAE. WT and irf3 −/− donors were immunised with MOG 35-55 in CFA medium, and peripheral lymphoid organs were harvested and reactivated with antigen in vitro in the presence of exogenous IL-23. CD4 + cells were purified and transferred intravenously to naive recipient WT mice. Strikingly, irf3 −/− CD4 + cells failed to induce EAE in any recipient animal in three independent experiments ( Figure 4C and Table 2). These findings demonstrate a key role for IRF3 in the pathogenicity of Th17 cells in EAE. Interestingly, as purified CD4 + T cells (WT or irf3 −/− ) were transferred to WT recipients, the findings from this study could have pointed towards a central role for direct, T-cell intrinsic IRF3 activity in influencing Th17 differentiation and pathogenicity. However, transfer of WT CD4 + cells to irf3 −/− recipients also failed to induce clinical EAE in any animals in two replicate experiments ( Figure 4C and Table 2), suggesting that T-cell extrinsic mechanisms are also involved in the lack of disease observed in IRF3-deficient recipients of WT CD4 + T cells. Thus, we sought to address whether CD4 + T cell intrinsic or extrinsic IRF3 activity influenced Th17 differentiation. Splenocytes and lymph nodes from WT and irf3 −/− mice were harvested 7 days after immunisation with MOG 35-55 . CD4 + and CD4 − fractions were prepared by immunomagnetic purification and co-cultured in combinations in which IRF3 deficiency was restricted to CD4 + cells, CD4 − cells, all cells or none. Cultures were reactivated with MOG 35-55 in Th17-polarising conditions. Strikingly, IL-17 production was impaired when all cells were deficient in IRF3 and when CD4 − cells were deficient in IRF3, but not when only CD4 + cells lacked IRF3 ( Figure 4D). These data show that, during antigen activation of CD4 + T cells, IRF3 activity in non-CD4 + T cells is required for maximal Th17 responses.
The findings of these studies are surprising, considering that type I IFN has been found to be protective in EAE in studies of IFN-α/β receptor-deficient mice and IFN-β-deficient mice [15][16][17]. Furthermore, we have previously shown that activation of TLR3 with polyinosinicpolycytidylic acid, which signals via IRF3, suppresses relapsing-remitting EAE in SJL mice [20]. This was also shown in chronic EAE by Tzima et al. [13]. However, these paradoxical findings may be explained in part by findings reported by Axtell et al. [21], who showed that, though IFN-β suppressed EAE in a Th1 model, the severity of EAE in an IL-23-driven Th17 model was in fact exacerbated by IFN-β. As signalling through IRF3 results in IFN-β production, IRF3 deficiency may abrogate such an exacerbating effect of IFN-β, particularly in IL-23-driven autoreactive T cells. In addition, Al-Salleeh and Petro have shown that the IL-23p19 promoter contains a binding site for IRF3 [22], and Smith et al. have reported increased IRF3 binding to the IL-23p19 promoter in monocytes taken from patients with systemic lupus erythematosus [23]. In a recent study of the inhibition of IL-23 by morphine, Ma et al. reported inhibition of IRF3 phosphorylation and suggested that this may underlie the observed inhibition of IL-23 [24]. Of note, however, we observed impaired IL-17 responses in cultures supplemented with IL-23; thus, a lack of IRF3driven IL-23 does not completely explain the decreased Th17 responses in our studies. In addition to recent discoveries pertaining to IL-23, IRF3 has been shown to inhibit Th1 responses by binding to the Il12b promoter and negatively regulating Il12b expression [25]. Indeed, irf3 −/− dendritic cells infected with vesicular stomatitis virus induced enhanced Th1 responses in naive syngeneic recipients associated with increased Ifng expression [25]. Similarly, in our present study, we observed enhanced Th1 differentiation during in vitro T cell activation in non-polarised and Th1-and Th17-polarising conditions.
It is tempting to speculate that such enhanced Th1 development in the absence of IRF3 inhibited Th17 development in our cultures. However, it is noteworthy that neutralisation of IFN-γ in our cultures did not restore Th17 polarisation in irf3 −/− cultures to levels of WT cells.

Conclusion
Collectively, the data reported here lend support to a role for IRF3 in driving the IL-23/Th17 axis and the pathogenesis of CNS autoimmune inflammation. These data indicate that IRF3 plays a critical role in the development of Th17 responses and MOG 35-55 -induced EAE and thus warrants investigation in human MS.   Cells were transferred into naive WT or irf3 −/− recipient mice. Mice were scored daily for clinical signs of disease (see Table 2). (D) Spleens and lymph nodes were harvested from WT and irf3 −/− mice that had been immunised with MOG 35-55 for 7 days. CD4 + and CD4 − populations were immunomagnetically purified and cultured in combinations as indicated. Cultures were reactivated with MOG 35-55 (25 μg/ml) in the presence of IL-23 (20 ng/ml), and IL-17 was measured by ELISA (n = 4). Data from one experiment representative of two or three replicate experiments are shown.